143 related articles for article (PubMed ID: 30220658)
1. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia.
Fiets RB; Staal AHJ; Cramer GE; Blijlevens NMA
Neth J Med; 2018 Sep; 76(7):330-335. PubMed ID: 30220658
[TBL] [Abstract][Full Text] [Related]
2. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Binzaid AA; Baqal OJ; Soheib M; Al Nahedh M; Samarkandi HH; Aljurf M
Gulf J Oncolog; 2021 Sep; 1(37):79-84. PubMed ID: 35152199
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
5. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
6. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
8. Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
Breccia M; Baccarani M; Rosti G; Cottone F; Cannella L; Guilhot F; Vignetti M; Efficace F
Health Qual Life Outcomes; 2017 Oct; 15(1):204. PubMed ID: 29047379
[TBL] [Abstract][Full Text] [Related]
9. Unusual case of dasatinib-associated acute bilateral hyphemas leading to blindness in a patient with chronic myeloid leukaemia.
Sharma S; Garg N; Ghiuzeli CM
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30150345
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
11. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
15. Selecting the best frontline treatment in chronic myeloid leukemia.
Yilmaz M; Abaza Y; Jabbour E
Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
[TBL] [Abstract][Full Text] [Related]
16. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
17. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukemia: First-line drug of choice.
Jabbour E
Am J Hematol; 2016 Jan; 91(1):59-66. PubMed ID: 26769227
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
20. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]